These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704 [TBL] [Abstract][Full Text] [Related]
7. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384 [TBL] [Abstract][Full Text] [Related]
8. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats. Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336 [TBL] [Abstract][Full Text] [Related]
9. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice. Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481 [TBL] [Abstract][Full Text] [Related]
10. Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages. Miranville A; Herling AW; Biemer-Daub G; Voss MD Obesity (Silver Spring); 2010 Dec; 18(12):2247-54. PubMed ID: 20379144 [TBL] [Abstract][Full Text] [Related]
11. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. Verty AN; Lockie SH; Stefanidis A; Oldfield BJ Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428 [TBL] [Abstract][Full Text] [Related]
13. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374 [TBL] [Abstract][Full Text] [Related]
14. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Lazzari P; Sanna A; Mastinu A; Cabasino S; Manca I; Pani L Behav Brain Res; 2011 Mar; 217(2):432-8. PubMed ID: 21074566 [TBL] [Abstract][Full Text] [Related]
15. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. Yu XX; Watts LM; Manchem VP; Chakravarty K; Monia BP; McCaleb ML; Bhanot S PLoS One; 2013; 8(7):e66923. PubMed ID: 23922646 [TBL] [Abstract][Full Text] [Related]
16. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077 [TBL] [Abstract][Full Text] [Related]
17. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Poncelet M; Maruani J; Calassi R; Soubrié P Neurosci Lett; 2003 Jun; 343(3):216-8. PubMed ID: 12770700 [TBL] [Abstract][Full Text] [Related]
18. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Rigamonti AE; Giordani C; Bonomo SM; Cella SG; Müller EE Eur J Pharmacol; 2006 Aug; 542(1-3):116-20. PubMed ID: 16806163 [TBL] [Abstract][Full Text] [Related]
19. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Costa B; Trovato AE; Colleoni M; Giagnoni G; Zarini E; Croci T Pain; 2005 Jul; 116(1-2):52-61. PubMed ID: 15936882 [TBL] [Abstract][Full Text] [Related]
20. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]